Cannabis Science buys patent for CBN compositions to treat sleep, anxiety and neurobehavioral disorders

Back to Article
Back to Article

Cannabis Science buys patent for CBN compositions to treat sleep, anxiety and neurobehavioral disorders

Bethan Rose Jenkins, Cannabis News Writer/Editorial

Hang on for a minute...we're trying to find some more stories you might like.

Email This Story

Cannabis Science, Inc. (OTC: CBIS), a U.S. developer of cannabinoid-based medicines, has proudly confirmed receipt of Issued US Patent Number 9,763,991 For Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders (ADHD), and Post-Traumatic Stress Disorders (PTSD), to name a few target indications.

A number of cannabis-derived extracts will be utilized by Cannabis Science to treat neurobehavioral disorders.

Cannabinol (CBN) is the preferred constituent of the plant for this patent. During studies, the CBN compositions demonstrated positive effects when used to treat sleep disorders, such as insomnia, and anxiety disorders, such as Attention Deficit Hyperactivity Disorder (ADHD) and Post-Traumatic Stress Disorder (PTSD).

What is CBN and what medicinal properties does the cannabinoid have?

Only trace amounts of the specific compound that Cannabis Sciences has patented is found in cannabis. The CBN content really goes through the roof when weed is exposed to the air, leaving it to age and develop more of the non-psychoactive cannabinoids. CBN is a metabolite of THC, which basically means that THC gradually metamorphoses into CBN over time.

One study revealed the plant has “potential immunosuppressive and anti-inflammatory activities.” Researchers discovered that CBN prefers to bind with the  “cannabinoid G-protein coupled receptor CB2, which is mainly expressed on a variety of immune cells, such as T-cells, B-cells, macrophages and dendritic cells.”

“Stimulation of CB2 receptors by cannabinol may both trigger apoptosis in these cells and inhibit the production of a variety of cytokines. Cannabinol exerts minimal affinity for CB1 and has a weak effect on the central nervous system,” the researchers added.

Cannabis for PTSD: Millions of Americans could benefit from medicinal pot

Cases involving veterans who have become addicted to opioid painkillers or driven to suicide as a result of medicinal weed restrictions have emerged more and more frequently over the last decade or so. The symptoms of PTSD are debilitating and emotionally draining, leaving many former veterans with anxiety issues, sleepless nights and depressive thoughts.

Thankfully, cannabis studies have exposed the plant’s ability to relieve all of the symptoms. When you consider the fact that some 50 million people in the U.S. suffer from a chronic sleep disorder, it becomes clear just how much of a difference legal cannabis products, including CBN compositions, can make.

Another reason why Cannabis Science has patented CBN compositions for neurobehavioral disorders is that cannabis can be used as a replacement for prescription drugs, such as opioids. Drugs that fall into the opiates class include heroin, morphine, and codeine, to name a few. They are addictive and can produce myriad adverse side effects. On hundreds of occasions every single day, those side effects are fatal.